Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic (Nasdaq: HOLX) announced that it will release its financial results for the third quarter of fiscal 2024 on July 29, 2024, after the market closes.
Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. To participate, dial (888) 394-8218 in the U.S. and Canada, or +1 (773) 305-6853 internationally, using access code 5372869. Alternatively, participants can join the webcast on Hologic's investor relations website.
A live and recorded webcast replay will be available on the website for 30 days, starting about two hours after the call concludes.
Hologic focuses on medical technologies that improve women's health and well-being through early detection and treatment.
Hologic (Nasdaq: HOLX) has announced its participation in two upcoming investor conferences. The company will present at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on May 29th at 10 a.m. CT. Additionally, Hologic will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois on June 4th at 8:40 a.m. CT. Both presentations will be webcast live and available for 30 days on the company’s investor relations website.
Hologic, Inc. (Nasdaq: HOLX) announced Q2 fiscal 2024 results, with revenue of $1,017.8M, GAAP EPS $0.72, Non-GAAP EPS $1.03, exceeding guidance. Total company organic revenue growth was 4.9% in constant currency. The company raised full-year revenue midpoint and EPS guidance.
Hologic, Inc. (Nasdaq: HOLX) announced the acquisition of Endomagnetics for $310 million, enhancing their breast surgery portfolio with innovative technologies. The deal is expected to expand options for breast cancer procedures, increase global access to advanced solutions, and improve patient care. Endomag's revenue in 2023 was approximately $35 million. The acquisition will be slightly dilutive to Hologic's non-GAAP earnings per share in 2024, break even in 2025, and accretive thereafter.